Skip to main content
Clinical Trials/NCT01554657
NCT01554657
Completed
Not Applicable

Five Versus Seven Day Antibiotic Course for the Treatment of Pneumonia in the Intensive Care Unit

Washington University School of Medicine0 sites46 target enrollmentJanuary 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pneumonia, Bacterial
Sponsor
Washington University School of Medicine
Enrollment
46
Primary Endpoint
Length of antibiotic therapy
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The goal of the study is to determine if patients who are being treated for pneumonia in the intensive care unit can be safely treated with five days of antibiotics (the current standard is seven to eight days). The goal is to determine if the investigators can minimize antibiotic complications while still treating the infection. Patients in the study are randomly assigned to either receive antibiotics for a goal of five days or a goal of seven days. Every patient is followed daily, and if they are not responding to the antibiotics, the treating team in the intensive care unit care can continue the antibiotics for a longer course regardless of what group the patient is assigned. The investigator's hypothesis is that patients in the five day treatment goal will be able to receive less antibiotics than patients in the seven day treatment goal without any adverse effects.

Detailed Description

This is a pilot study to determine if patients with pneumonia in the intensive care unit can safely receive five days of antibiotics. All patients admitted to the medical and surgical intensive care units at Barnes-Jewish Hospital with pneumonia will be screened for the inclusion and exclusion criteria. Patients will be randomized by sealed envelopes in groups of six to a five or seven day course of antibiotics. The choice of the antibiotic to be used is determined by the intensive care unit treating team. The patients will NOT be randomized to a specific antibiotic. The patients will be followed for a clinical response by improvement in maximum daily temperature, white blood cell count, and PaO2 to FiO2 ratio. Antibiotics can continue past the goal duration for patients in either group if the above criteria are not met or if the attending physician in the intensive care unit feels that a longer course is needed. The treating team in the intensive care unit will not be blinded to the patient's treatment assignment.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
February 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • New diagnosis of pneumonia
  • Patient in medical or surgical intensive care unit
  • Age greater or equal than 18 years old

Exclusion Criteria

  • Neutropenia
  • Recipient of a solid organ or bone marrow transplant
  • Bacteremia
  • Presence of Acinetobacter baumannii or Stenotrophomonas maltophilia from a respiratory tract culture
  • Presence of a second infection requiring antibiotic therapy
  • Pregnancy
  • Enrollment in another clinical study
  • Patient or surrogate unable to provide informed consent
  • Attending intensive care unit physician declined enrollment in the study

Outcomes

Primary Outcomes

Length of antibiotic therapy

Time Frame: 28 days

Secondary Outcomes

  • Mortality(28 days)
  • Hospital Length of Stay(28 Days)
  • Clostridium difficile diarrhea(28 Days)
  • Development of a new multi-drug resistant bacteria from a lower respiratory tract culture(28 days)
  • Recurrent lower respiratory tract infection(28 days)

Similar Trials